Your session is about to expire
← Back to Search
Cancer Vaccine + Pembrolizumab for Melanoma
Study Summary
This trial will explore whether a cancer vaccine is safe and effective when combined with other treatments for melanoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have previously been treated with specific immune therapy or virus-based cancer treatment.I have been diagnosed with eye melanoma.My blood, liver, and kidney functions are all within normal ranges.I've had treatment for advanced melanoma, but not within the last few weeks.I have a history of heart disease.I plan to try for a child during the study and up to 4 months after.I agree to have tumor biopsies during the study.My melanoma is at stage IIIB, IIIC, or IV.You are allergic to GM-CSF.I have or had lung inflammation not caused by an infection.I have not been treated before, except with BRAF and MEK inhibitors, and can receive pembrolizumab.I have been cancer-free for at least 5 years, except for blood or solid tumor cancers.
- Group 1: Experimental Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies for prospective participants in this clinical study?
"Unfortunately, this clinical trial is not currently accepting patients. The data posted to clinicaltrials.gov shows that it was initially listed on July 9th 2018 and last edited on November 16th 2022; however, there are 753 other trials seeking participants at the moment."
How many sites are utilized for the management of this trial?
"Four medical sites are responsible for conducting this trial including University of Iowa Carver College of Medicine in Iowa City, St. Luke's University Health Network in Easton, and John Wayne Cancer Center in Santa Monica; plus an additional 4 locations."
To what extent does UV1 pose a risk to humans?
"Due to the limited safety and efficacy data available, our team assigned UV1 a score of one on the risk scale."
Share this study with friends
Copy Link
Messenger